Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program
出版年份 2012 全文链接
标题
Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program
作者
关键词
-
出版物
PEDIATRIC BLOOD & CANCER
Volume 60, Issue 4, Pages 633-641
出版商
Wiley
发表日期
2012-07-02
DOI
10.1002/pbc.24235
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors
- (2011) J. Tabernero et al. CLINICAL CANCER RESEARCH
- Mutations and Deletions of the TP53 Gene Predict Nonresponse to Treatment and Poor Outcome in First Relapse of Childhood Acute Lymphoblastic Leukemia
- (2011) Jana Hof et al. JOURNAL OF CLINICAL ONCOLOGY
- Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3
- (2011) T. Van Maerken et al. MOLECULAR CANCER THERAPEUTICS
- Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program
- (2011) Malcolm A. Smith et al. PEDIATRIC BLOOD & CANCER
- Nutlin-3a Is a Potential Therapeutic for Ewing Sarcoma
- (2010) K. I. Pishas et al. CLINICAL CANCER RESEARCH
- The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
- (2010) K. Kojima et al. MOLECULAR CANCER THERAPEUTICS
- Guidelines for accurate EC50/IC50 estimation
- (2010) J. L. Sebaugh PHARMACEUTICAL STATISTICS
- Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14ARF-MDM2-p53 axis
- (2009) T Van Maerken et al. CELL DEATH AND DIFFERENTIATION
- Restoration of p53 Pathway by Nutlin-3 Induces Cell Cycle Arrest and Apoptosis in Human Rhabdomyosarcoma Cells
- (2009) M. Miyachi et al. CLINICAL CANCER RESEARCH
- Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53
- (2009) Tom Van Maerken et al. JNCI-Journal of the National Cancer Institute
- Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
- (2008) Sanjeev Shangary et al. Annual Review of Pharmacology and Toxicology
- Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance
- (2008) J A McCubrey et al. LEUKEMIA
- MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
- (2008) L Gu et al. LEUKEMIA
- Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program
- (2007) Peter J. Houghton et al. PEDIATRIC BLOOD & CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now